Proteomic analysis of early response lymph node proteins in mice treated with titanium dioxide nanoparticles

Journal of Proteomics

Volumn 74, Issue 12, 2011, Pages 2745-2759

  Gao, Yuan ^a   Gopee, Neera V ^a   Howard, Paul C ^a   Yu, Li Rong ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

16O 18O labeling; LC MS MS; Mass spectrometry; Mouse lymph node; Proteomics; TiO2 nanoparticle

Indexed keywords

3 HYDROXYISOBUTYRATE DEHYDROGENASE; ACETYL COENZYME A CARBOXYLASE BETA; ACYLGLYCEROL LIPASE; CALGRANULIN A; CALGRANULIN B; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR SUBUNIT 6; ENOYL COENZYME A HYDRATASE; ESTROGEN RECEPTOR ALPHA; FATTY ACID BINDING PROTEIN; HISTONE H1; HISTONE H2A; HISTONE H2B; HISTONE H4; INTERFERON GAMMA INDUCIBLE PROTEIN 30; LACTOFERRIN; LAMIN B; MYC PROTEIN; MYOSIN LIGHT CHAIN; NANOPARTICLE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN; PYRUVATE CARBOXYLASE; RETICULOCALBIN 2; TITANIUM DIOXIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; FATTY ACID METABOLISM; FEMALE; IMMUNE RESPONSE; LIPID METABOLISM; LIQUID CHROMATOGRAPHY; LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY;

ANIMALS; BIOCOMPATIBLE MATERIALS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LYMPH NODES; MICE; NANOPARTICLES; PROTEOME; PROTEOMICS; TITANIUM;

MUS;

EID: 81055140401     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2011.08.009     Document Type: Article

References (64)

1. Schultz W.B., Barclay L. A hard pill to swallow: barriers to effective FDA regulation of nanotechnology-based dietary supplements 2009, 1-28. Woodrow Wilson International Center for Scholars, Washington, DC.
2. Dobrovolskaia M.A., McNeil S.E. Immunological properties of engineered nanomaterials. Nat Nanotechnol 2007, 2:469-478.
3. Lammers T., Hennink W.E., Storm G. Tumour-targeted nanomedicines: principles and practice. Br J Cancer 2008, 99:392-397.
4. Handy R.D., Shaw B.J. Toxic effects of nanoparticles and nanomaterials: implications for public health, risk assessment and the public perception of nanotechnology. Health Risk Soc 2007, 9:125-144.
5. Maynard A.D., Aitken R.J., Butz T., Colvin V., Donaldson K., Oberdorster G., Philbert M.A., Ryan J., Seaton A., Stone V., Tinkle S.S., Tran L., Walker N.J., Warheit D.B. Safe handling of nanotechnology. Nature 2006, 444:267-269.
6. Sundaram S.K., Weber T.J. Special issue: on nanotoxicity. Int J Nanotechnol 2008, 5:1-2.
7. Sweet L., Strohm B. Nanotechnology - life-cycle risk management. Hum Ecol Risk Assess 2006, 12:528-551.
8. Landsiedel R., Ma-Hock L., Kroll A., Hahn D., Schnekenburger J., Wiench K., Wohlleben W. Testing metal-oxide nanomaterials for human safety. Adv Mater 2010, 22:2601-2627.
9. Xu L.G., Liu Y., Bai R., Chen C.Y. Applications and toxicological issues surrounding nanotechnology in the food industry. Pure Appl Chem 2010, 82:349-372.
10. Fischer H.C., Chan W.C. Nanotoxicity: the growing need for in vivo study. Curr Opin Biotech 2007, 18:565-571.
11. Oberdorster G., Oberdorster E., Oberdorster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect. 2005, 113:823-839.
12. Holgate S.T. Exposure, uptake, distribution and toxicity of nanomaterials in humans. J Biomed Nanotechnol 2010, 6:1-19.
13. Sugibayashi K., Todo H., Kimura E. Safety evaluation of titanium dioxide nanoparticles by their absorption and elimination profiles. J Toxicol Sci 2008, 33:293-298.
14. Fabian E., Landsiedel R., Ma-Hock L., Wiench K., Wohlleben W., van Ravenzwaay B. Tissue distribution and toxicity of intravenously administered titanium dioxide nanoparticles in rats. Arch Toxicol 2008, 82:151-157.
15. Kim S., Lim Y.T., Soltesz E.G., De Grand A.M., Lee J., Nakayama A., Parker J.A., Mihaljevic T., Laurence R.G., Dor D.M., Cohn L.H., Bawendi M.G., Frangioni J.V. Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nat Biotechnol 2004, 22:93-97.
16. Gopee N.V., Roberts D.W., Webb P., Cozart C.R., Siitonen P.H., Warbritton A.R., Yu W.W., Colvin V.L., Walker N.J., Howard P.C. Migration of intradermally injected quantum dots to sentinel organs in mice. Toxicol Sci 2007, 98:249-257.
17. Reddy S.T., van der Vlies A.J., Simeoni E., Angeli V., Randolph G.J., O'Neil C.P., Lee L.K., Swartz M.A., Hubbell J.A. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol 2007, 25:1159-1164.
18. Mortensen L.J., Oberdorster G., Pentland A.P., DeLouise L.A. In vivo skin penetration of quantum dot nanoparticles in the murine model: the effect of UVR. Nano Lett 2008, 8:2779-2787.
19. Gopee N.V., Roberts D.W., Webb P., Cozart C.R., Siitonen P.H., Latendresse J.R., Warbitton A.R., Yu W.W., Colvin V.L., Walker N.J., Howard P.C. Quantitative determination of skin penetration of PEG-coated CdSe quantum dots in dermabraded but not intact SKH-1 hairless mouse skin. Toxicol Sci 2009, 111:37-48.
20. Gontier E., Ynsa M.-D., Biro T., Hunyadi J., Kiss B., Gaspar K., Pinheiro T., Silva J.-N., Filipe P., Stachura J., Dabros W., Reinert T., Butz T., Moretto P., Surleve-Bazeille J.-E. Is there penetration of titania nanoparticles in sunscreens through skin? A comparative electron and ion microscopy study. Nanotoxicology 2008, 2:218-231.
21. 2 particles. Toxicol Sci 2010, 115:156-166.
22. Liao C.M., Chiang Y.H., Chio C.P. Assessing the airborne titanium dioxide nanoparticle-related exposure hazard at workplace. J Hazard Mater 2009, 162:57-65.
23. 2 rods and dots in rats: toxicity is not dependent upon particle size and surface area. Toxicol Sci 2006, 91:227-236.
24. 2 particles: differential responses related to surface properties. Toxicology 2007, 230:90-104.
25. Lee K., Yang Y.S., Kwon S.J., Lee J.S., Choi S.J., Seo H.S., Kang M.S., Lee B.C., Kim S.N., Yang H.S., Han Y.A., Ryu H.J., Heo J.D., Cho K.H., Song C.W. Lung injury study by 15days inhalation exposure of titanium dioxide nanoparticles in rats. Toxicol Lett 2009, 189:S186.
26. Grassian V.H., Adamcakova-Dodd A., Pettibone J.M., O'Shaughnessy P.T., Thorne P.S. Inflammatory response of mice to manufactured titanium dioxide nanoparticles: comparison of size effects through different exposure routes. Nanotoxicology 2007, 1:211-226.
27. 2 and liver DNA from mice in vivo. Nanoscale Res Lett 2010, 5:108-115.
28. Trouiller B., Reliene R., Westbrook A., Solaimani P., Schiestl R.H. Titanium dioxide nanoparticles induce DNA damage and genetic instability in vivo in mice. Cancer Res 2009, 69:8784-8789.
29. Li N., Duan Y.M., Hong M.M., Zheng L., Fei M., Zhao X.Y., Wang J., Cui Y.L., Liu H.T., Cai J.W., Gong S.J., Wang H., Hong F.S. Spleen injury and apoptotic pathway in mice caused by titanium dioxide nanoparticules. Toxicol Lett 2010, 195:161-168.
30. Kang S.J., Kim B.M., Lee Y.J., Chung H.W. Titanium dioxide nanoparticles trigger p53-mediated damage response in peripheral blood lymphocytes. Environ Mol Mutagen 2008, 49:399-405.
31. 2 with lysozyme: insights into the enzyme toxicity of nanosized particles. Environ Sci Pollut Res 2010, 17:798-806.
32. 2 nanoparticles promote beta-amyloid fibrillation in vitro. Biochem Biophys Res Commun 2008, 373:315-318.
33. Lundqvist M., Stigler J., Elia G., Lynch I., Cedervall T., Dawson K.A. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci U S A 2008, 105:14265-14270.
34. Gessner A., Waicz R., Lieske A., Paulke B., Mader K., Muller R.H. Nanoparticles with decreasing surface hydrophobicities: influence on plasma protein adsorption. Int J Pharm 2000, 196:245-249.
35. Asuri P., Bale S.S., Karajanagi S.S., Kane R.S. The protein-nanomaterial interface. Curr Opin Biotechnol 2006, 17:562-568.
36. Maurer-Jones M.A., Lin Y.S., Haynes C.L. Functional assessment of metal oxide nanoparticle toxicity in immune cells. ACS Nano 2010, 4:3363-3373.
37. Izhaky D., Pecht I. What else can the immune system recognize?. Proc Natl Acad Sci U S A 1998, 95:11509-11510.
38. 2 nanoparticles. Mol Cell Toxicol 2010, 6:97-104.
39. Bu Q., Yan G.Y., Deng P.C., Peng F., Lin H.J., Xu Y.Z., Cao Z.X., Zhou T., Xue A.Q., Wang Y.L., Cen X.B., Zhao Y.L. NMR-based metabonomic study of the sub-acute toxicity of titanium dioxide nanoparticles in rats after oral administration. Nanotechnology 2010, 21. doi:10.1088/0957-4484/21/12/125105.
40. 2 nanoparticles induce cytotoxicity and protein expression alteration in HaCaT cells. Part Fibre Toxicol 2010, 7. doi:10.1186/1743-8977-7-1.
41. Schnolzer M., Jedrzejewski P., Lehmann W.D. Protease-catalyzed incorporation of O-18 into peptide fragments and its application for protein sequencing by electrospray and matrix-assisted laser desorption/ionization mass spectrometry. Electrophoresis 1996, 17:945-953.
42. Blonder J., Hale M.L., Chan K.C., Yu L.R., Lucas D.A., Conrads T.P., Zhou M., Popoff M.R., Issaq H.J., Stiles B.G., Veenstra T.D. Quantitative profiling of the detergent-resistant membrane proteome of Iota-b toxin induced Vero cells. J Proteome Res 2005, 4:523-531.
43. Yu L.R., Zhu Z.Y., Chan K.C., Issaq H.J., Dimitrov D.S., Veenstra T.D. Improved titanium dioxide enrichment of phosphopeptides from HeLa cells and high confident phosphopeptide identification by cross-validation of MS/MS and MS/MS/MS spectra. J Proteome Res 2007, 6:4150-4162.
44. Yu L.R., Chan K.C., Tahara H., Lucas D.A., Chatterjee K., Issaq H.J., Veenstra T.D. Quantitative proteomic analysis of human breast epithelial cells with differential telomere length. Biochem Biophys Res Commun 2007, 356:942-947.
45. Fenselau C., Yao X.D. O-18(2)-labeling in quantitative proteomic strategies: a status report. J Proteome Res 2009, 8:2140-2143.
46. Stewart I.I., Thomson T., Figeys D. O-18 labeling: a tool for proteomics. Rapid Commun Mass Spectrom 2001, 15:2456-2465.
47. Storms H.F., van der Heijden R., Tjaden U.R., van der Greef J. Considerations for proteolytic labeling-optimization of O-18 incorporation and prohibition of back-exchange. Rapid Commun Mass Spectrom 2006, 20:3491-3497.
48. Petritis B.O., Qian W.J., Camp D.G., Smith R.D. A simple procedure for effective quenching of trypsin activity and prevention of O-18-labeling back-exchange. J Proteome Res 2009, 8:2157-2163.
49. 16O labeling and linear Ion trap mass spectrometry: application to the study of vascular endothelial growth factor-induced angiogenesis in endothelial cells. Mol Cell Proteomics 2009, 8:1130-1149.
50. 18O Labeling. Mol Cell Proteomics 2011, 10. 10.1074/mcp.M1110.003335, 1-14.
51. Carroll J.S., Meyer C.A., Song J., Li W., Geistlinger T.R., Eeckhoute J., Brodsky A.S., Keeton E.K., Fertuck K.C., Hall G.F., Wang Q.B., Bekiranov S., Sementchenko V., Fox E.A., Silver P.A., Gingeras T.R., Liu X.S., Brown M. Genome-wide analysis of estrogen receptor binding sites. Nat Genet 2006, 38:1289-1297.
52. Millevoi S., Loulergue C., Dettwiler S., Karaa S.Z., Keller W., Antoniou M., Vagner S. An interaction between U2AF 65 and CF I(m) links the splicing and 3' end processing machineries. EMBO J 2006, 25:4854-4856.
53. Kerkhoff C., Klempt M., Sorg C. Novel insights into structure and function of MRP8 (S100A8) and MRP14 (S100A9). BBA-Mol Cell Res 1998, 1448:200-211.
54. Naranjo V., Villar M., Martin-Hernando M.P., Vidal D., Hofle U., Gortazar C., Kocan K.M., Vazquez J., de la Fuente J. Proteomic and transcriptomic analyses of differential stress/inflammatory responses in mandibular lymph nodes and oropharyngeal tonsils of European wild boars naturally infected with Mycobacterium bovis. Proteomics 2007, 7:220-231.
55. Kimura Y., Yokoyama R., Ishizu Y., Nishigaki T., Murahashi Y., Hijikata A., Kitamura H., Ohara O. Construction of quantitative proteome reference maps of mouse spleen and lymph node based on two-dimensional gel electrophoresis. Proteomics 2006, 6:3833-3844.
56. Leak L.V., Liotta L.A., Krutzsch H., Jones M., Fusaroa V.A., Ross S.J., Zhaos Y.M., Petricoin E.F. Proteomic analysis of lymph. Proteomics 2004, 4:753-765.
57. Shriver C., Sullivan A., Somiari S., Russell S., Heckman C., Hooke J., Somiari R.I. Proteomics analysis of breast tumors and lymph nodes by 2-dimensional differential in-gel electrophoresis. Ann Surg Oncol 2003, 10:S15.
58. Antonucci F., Chilosi M., Santacatterina M., Herbert B., Righetti P.G. Proteomics and immunomapping of reactive lymph-node and lymphoma. Electrophoresis 2002, 23:356-362.
59. Manolova V., Flace A., Bauer M., Schwarz K., Saudan P., Bachmann M.F. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol 2008, 38:1404-1413.
60. Choi H.S., Ashitate Y., Lee J.H., Kim S.H., Matsui A., Insin N., Bawendi M.G., Semmler-Behnke M., Frangioni J.V., Tsuda A. Rapid translocation of nanoparticles from the lung airspaces to the body. Nat Biotech 2010, 28:1300-1303.
61. Bhardwaj R.S., Zotz C., Zwadloklarwasser G., Roth J., Goebeler M., Mahnke K., Falk M., Meinardushager G., Sorg C. The calcium-binding proteins MRP8 and MRP14 form a membrane-associated heterodimer in a subset of monocytes/macrophages present in acute but absent in chronic inflammatory lesions. Eur J Immunol 1992, 22:1891-1897.
62. Rosen E.D., Spiegelman B.M. PPAR gamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001, 276:37731-37734.
63. Nielsen R., Pedersen T.A., Hagenbeek D., Moulos P., Siersbaek R., Megens E., Denissov S., Borgesen M., Francoijs K.J., Mandrup S., Stunnenberg H.G. Genome-wide profiling of PPAR gamma:RXR and RNA polymerase II occupancy reveals temporal activation of distinct metabolic pathways and changes in RXR dimer composition during adipogenesis. Gene Dev 2008, 22:2953-2967.
64. Gearhart J., Pashos E.E., Prasad M.K. Pluripotency redux - advances in stem-cell research. N Engl J Med 2007, 357:1469-1472.